I'm still trying to figure out why Eli Lily acquired point pharma. Their lead asset is equivocal for being BIC. Did they acquire then for their platform and/or manufacturing? @Davisite
On another note, if pluvicto ends up being equivocal in OS vs chemo and cu67 continues its current trajectory, it could mean cu67 may have a $5b TAM market to itself (after a H2H clinical trial vs chemo).
and then there is the nonPSMA PC asset, that covers ~20% of PC recurrence, currently without an approved radioligand therapy for it. Considering SABRE is probably going to be demonstrating uptake, the likelihood of success for therapy is higher.
it would seem like highway robbery if Alan isn't trying to court multiple pharmas.
Research/Valuation, page-168
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.09 |
Change
-0.210(4.88%) |
Mkt cap ! $1.272B | |||
| Open | High | Low | Value | Volume |
| $4.30 | $4.30 | $4.08 | $3.493M | 835.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 7459 | $4.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.12 | 9361 | 1 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$4.10 |
Change
-0.210 ( 4.15 %) |
||||
| Open | High | Low | Volume | ||
| $4.17 | $4.29 | $4.08 | 50363 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| CU6 (ASX) Chart |